

[Isoniazid](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.2. Antibacterials](#) [6.2.5. Antituberculosis medicines](#)

ATC codes: [J04AC01](#)

EMLc

Indication

Tuberculosis ICD11 code: [1B4Z](#)

INN

Isoniazid

Medicine type

Chemical agent

List type

Core

Additional notes

WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.

Formulations

Oral > Solid > dispersible tablet: 100 mg (scored) (EMLc)

Oral > Solid > tablet: 100 mg ; 300 mg

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Isoniazid](#)

DrugBank

[Isoniazid](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.